12 Month Price Forecast For CRL
Distance to CRL Price Forecasts
CRL Price Momentum
๐ค Considering Charles River (CRL)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 12:59 PM UTC
CRL Analyst Ratings & Price Targets
Based on our analysis of 32 Wall Street analysts, CRL has a neutral consensus with a median price target of $183.00 (ranging from $152.00 to $260.12). The overall analyst rating is Buy (6.3/10). Currently trading at $151.99, the median forecast implies a 20.4% upside. This outlook is supported by 5 Buy, 12 Hold, and 3 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRL Analyst Consensus
CRL Price Target Range
Latest CRL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRL.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 5, 2025 | Morgan Stanley | Ricky Goldwasser | Equal-Weight | Maintains | $184.00 |
Feb 3, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $175.00 |
Jan 23, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $190.00 |
Jan 22, 2025 | William Blair | Max Smock | Market Perform | Downgrade | $0.00 |
Jan 17, 2025 | UBS | Dan Leonard | Neutral | Downgrade | $185.00 |
Jan 14, 2025 | William Blair | Max Smock | Outperform | Reiterates | $0.00 |
Dec 13, 2024 | B of A Securities | Derik De Bruin | Neutral | Maintains | $210.00 |
Nov 11, 2024 | TD Cowen | Charles Rhyee | Hold | Maintains | $227.00 |
Nov 7, 2024 | UBS | Dan Brennan | Buy | Maintains | $250.00 |
Nov 7, 2024 | Evercore ISI Group | Ross Muken | In-Line | Maintains | $225.00 |
Oct 23, 2024 | CLSA | Underperform | Initiates | $167.00 | |
Oct 14, 2024 | Redburn Atlantic | Jamie Clark | Sell | Initiates | $151.00 |
Oct 7, 2024 | Evercore ISI Group | Ross Muken | In-Line | Downgrade | $190.00 |
Oct 2, 2024 | B of A Securities | Derik De Bruin | Neutral | Downgrade | $215.00 |
Oct 1, 2024 | Citigroup | Patrick Donnelly | Sell | Downgrade | $175.00 |
Sep 20, 2024 | Baird | Eric Coldwell | Neutral | Maintains | $190.00 |
Aug 12, 2024 | TD Cowen | Charles Rhyee | Hold | Maintains | $203.00 |
Aug 8, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $210.00 |
Aug 8, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $250.00 |
Aug 8, 2024 | Baird | Eric Coldwell | Neutral | Downgrade | $191.00 |
Stocks Similar to Charles River Laboratories International Inc
The following stocks are similar to Charles River based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Charles River Laboratories International Inc (CRL) Financial Data
Charles River Laboratories International Inc has a market capitalization of $7.77B with a P/E ratio of 19.0x. The company generates $4.06B in trailing twelve-month revenue with a 10.4% profit margin.
Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of +14.7% and return on equity of +11.9%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Charles River Laboratories International Inc (CRL) Company Overview
About Charles River Laboratories International Inc
Provides drug discovery and safety testing services.
The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. It generates revenue by selling research models and services, conducting preclinical drug discovery and safety assessments, and providing quality control testing for pharmaceuticals and consumer products.
Founded in 1947 and headquartered in Wilmington, Massachusetts, the company serves clients globally, including those in the United States, Europe, Canada, and the Asia Pacific. Its services support biopharmaceutical companies in drug development processes, making it a critical player in the healthcare and pharmaceutical industries.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
20,400
CEO
Mr. James C. Foster J.D.
Country
United States
IPO Year
2000
Website
www.criver.comCharles River Laboratories International Inc (CRL) Latest News & Analysis
Charles River (CRL) may not meet earnings expectations in its upcoming report due to lacking key factors for a potential earnings beat. Investors should prepare accordingly.
Charles River's lack of key ingredients for an earnings beat may signal weaker performance, potentially impacting stock price and investor sentiment.
Charles River and Deciphex are collaborating to enhance image management solutions and develop new AI tools for toxicologic pathology.
Charles River and Deciphex's partnership in AI for toxicologic pathology signals innovation in biotech, potentially enhancing efficiency and accuracy in drug development, impacting market competitiveness.
Charles River's fourth-quarter revenues are expected to benefit from growth in the Manufacturing and RMS segments.
Increased growth in Manufacturing and RMS segments suggests strong performance for Charles River, potentially boosting revenue and impacting stock value positively.
Charles River Laboratories has scheduled its fourth-quarter 2024 earnings release and 2025 guidance conference call.
Charles River Laboratories' upcoming earnings release and guidance can signal future performance, impacting stock valuation and investor sentiment. Market reactions may follow based on reported results.
CRL has launched Apollo for CRADL, enhancing its technology integration across its portfolio.
CRL's integration of Apollo into CRADL enhances its technology offerings, potentially improving efficiency and competitiveness, which can positively impact future revenue and stock performance.
Charles River has expanded its Apollo ecosystem to provide tailored client experiences that enhance data-driven decision-making.
Charles River's expansion of the Apollo ecosystem enhances its service offerings, potentially increasing client retention and revenue, which could positively impact stock performance.
Frequently Asked Questions About CRL Stock
What is Charles River Laboratories International Inc's (CRL) stock forecast for 2025?
Based on our analysis of 32 Wall Street analysts, Charles River Laboratories International Inc (CRL) has a median price target of $183.00. The highest price target is $260.12 and the lowest is $152.00.
Is CRL stock a good investment in 2025?
According to current analyst ratings, CRL has 5 Buy ratings, 12 Hold ratings, and 3 Sell ratings. The stock is currently trading at $151.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CRL stock?
Wall Street analysts predict CRL stock could reach $183.00 in the next 12 months. This represents a 20.4% increase from the current price of $151.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Charles River Laboratories International Inc's business model?
The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. It generates revenue by selling research models and services, conducting preclinical drug discovery and safety assessments, and providing quality control testing for pharmaceuticals and consumer products.
What is the highest forecasted price for CRL Charles River Laboratories International Inc?
The highest price target for CRL is $260.12 from at , which represents a 71.1% increase from the current price of $151.99.
What is the lowest forecasted price for CRL Charles River Laboratories International Inc?
The lowest price target for CRL is $152.00 from at , which represents a 0.0% increase from the current price of $151.99.
What is the overall CRL consensus from analysts for Charles River Laboratories International Inc?
The overall analyst consensus for CRL is neutral. Out of 32 Wall Street analysts, 5 rate it as Buy, 12 as Hold, and 3 as Sell, with a median price target of $183.00.
How accurate are CRL stock price projections?
Stock price projections, including those for Charles River Laboratories International Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.